bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P2-14-09: Results from a novel educational program to help nurses when discussing the Oncotype DX Breast Recurrence Score® with their patients
Authors: Fallowfield Lesley , May Shirley , Ramirez Amanda , Fryer Nina , Paramore Andrew , Jenkins Valerie 
Published: March 2020

Abstract
Background Discussing risk of recurrence and potential treatment benefit in early breast cancer can be challenging, especially when dealing with anxious patients and/or those with difficult social circumstances. UK patients usually have access to specialist breast care nurses (SBCN) who discuss in further detail the implications that the Oncotype DX Breast Recurrence Score® result may have for:- treatment decisions, risks and benefits of chemotherapy and the potential impact on patients’ well-being and lifestyle. We developed an innovative communication skills workshop to assist SBCNs with these encounters. Methods The 6 hour workshops comprised:- 2 didactic presentations, one on the data underpinning the OncotypeDX® risk scores and cut-offs post TAILORx and another on the psychology of risk which included interactive exercises about numeracy, communication, and tolerance to uncertainty. Attendees then split into small groups for two practical sessions led by experienced facilitators. First they viewed one of 2 filmed scenarios of oncologists explaining Recurrence Score results with patients. The SBCNs then met with the same simulated patient just seen on film, who was now ‘in clinic’ a week later and keen to discuss her test result further. During these practical sessions facilitators engaged and encouraged the SBCNs to consider and practice different ways of handling the patients’ difficult questions. At completion of each session the simulated patients provided feedback and suggestions. Attendees completed 11 item pre/post workshop questionnaires probing their self-confidence when discussing complex issues surrounding the Recurrence Score® result. Results A total of 69 UK SBCNs participated. There were significant and positive improvements in mean change scores of self-rated confidence for all 11 issues, (P&lt;0.004; Bonferonni) including handling discussions of scores post TAILORx. Workshops were rated as informative (9.6/10), useful (9.5/10) and enjoyable (9.6/10) with 68/69 (99%) recommending it to colleagues. Conclusion Nurses can play an important role helping patients’ decision-making; they are also usually fearful of role-play but most found the innovative practical sessions especially helpful. Our results showed that improved self-confidence, a key element required to lead to a transfer of communication skills into a clinic setting, was achieved in this six hour workshop.
Citation Format: Lesley Fallowfield, Shirley May, Amanda Ramirez, Nina Fryer, Andrew Paramore, Valerie Jenkins. Results from a novel educational program to help nurses when discussing the Oncotype DX Breast Recurrence Score® with their patients [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-14-09.
Abstract P2-16-07: Randomized controlled trial of neoadjuvant eribulin mesylate versus paclitaxel in women with operable breast cancer (JONIE-3 study)
Authors: Kawate Takahiko , Ishikawa Takashi , Miura Daishu , Hasegawa Yoshie , Tachibana Akihiko , Horiguchi Jun , Hayashi Mitsuhiro , Miyashita Masaru , Kubota Tomoyuki , Narui Kazutaka , Suzuki Masato , Akazawa Kouhei , Kohno Norio 
Published: March 2020

Abstract
Background: Eribulin mesylate (ERI) improved the overall survival in metastatic breast cancer (BC) patients. However, the efficacy has not been reported in early breast cancer. We performed the neoadjuvant chemotherapy (NAC) study based on hypothesis that ERI is less toxic, particularly in peripheral neuropathy, and has similar efficacy to paclitaxel (PTX) in patients with operable BC. Methods: This is a multicenter open label randomized phase 2 study (UMIN000012817). Patients were randomly assigned to either ERI (1.4mg/m2, d1 and d8, q21 days, 4 cycles) followed by FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2) (ERI-FEC) or PTX (80mg/m2, weekly, 12 cycles) followed by FEC (PTX-FEC) with stratified by ER, HER2, and menopausal status. Trastuzumab was added in patients with HER2 positive disease. Primary endpoint was the incidence of peripheral sensory and motor neuropathy (PSN and PMN) with Grade 1 or higher according to CTCAE ver.4.0. Secondary endpoints were pathological complete response (pCR) rates (ypT0/is/ypN0), clinical response rates (CR+PR), adverse events, disease-free survival (DFS) and patient neurotoxicity questionnaire (PNQ) analysis. Here, we report 3 year’s DFS and PNQ analysis in this study Results: Between December 2013 to March 2016, 121 cases were enrolled and 5 cases were excluded from the primary assessment. One hundred sixteen cases were finally randomized and treated by ERI-FEC in 58 cases and PTX-FEC in 57 cases. A median follow-up time of ERI-FEC and PTX-FEC was 54.2 and 51.4 months, respectively. Three year-DFS rate were 89.7% in the ERI-FEC group (95% CI 51.1 - 57.3) and 86.0% in the PTX-FEC group. (p=0.561). The incidences of PSN and PMN were significantly lower in the ERI-FEC group than the PAX-FEC group at the end of treatments (previously reported). PNQ analysis after treatments is now undergone. Conclusion: DFS was not different between them. Although the pCR rate was lower in ERI-FEC than PAC-FEC as reported at the previous meeting. ERI was more favorable on adverse events than PTX during NAC treatments. Long-term results on neurotoxicity of these two drugs will be presented at the meeting.
Citation Format: Takahiko Kawate, Takashi Ishikawa, Daishu Miura, Yoshie Hasegawa, Akihiko Tachibana, Jun Horiguchi, Mitsuhiro Hayashi, Masaru Miyashita, Tomoyuki Kubota, Kazutaka Narui, Masato Suzuki, Kouhei Akazawa, Norio Kohno. Randomized controlled trial of neoadjuvant eribulin mesylate versus paclitaxel in women with operable breast cancer (JONIE-3 study) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-16-07.
Abstract P2-16-11: Impact of progesterone receptor status on response to neoadjuvant chemotherapy in oestrogen receptor positive breast cancer patients
Authors: Boland Michael R , Ryan Eanna J , Nugent Timothy , Gilroy Darina , Kennedy John , Alazawi Dhaffir , Boyle Terence J , Connolly Elizabeth M 
Published: March 2020

Abstract
Introduction Breast cancer patients respond differently to neoadjuvant chemotherapy (NAC) based on hormone receptor subtype. Oestrogen receptor positive/Her-2 receptor negative (ER+HER-) patients respond poorest but the effect of progesterone receptor (PR) status on response within this group has not been elucidated. The aim of this study was to assess the impact of PR status on response to NAC in ER+HER- breast cancer patients. Methods All patients receiving NAC over a seven-year period (2011-2017) were retrospectively identified from a prospectively maintained database within a specialised breast referral unit. Clinicopathological details were collated for all patients found to be ER+HER-. Primary outcomes including breast complete pathological response (PCR) rate and axillary PCR rate were compared between patients found to be progesterone receptor positive and negative. Secondary outcomes including grade and presence of lymphovascular invasion were also assessed. Results 206 patients were identified (151 in the ER+PR+HER- group and 55 in the ER+PR-HER- group). When compared with the PR+ group, patients found to be PR negative were more likely to achieve a breast PCR (3.3% vs 25.4%; Chi Square test; p=0.001), which was confirmed on multivariate analysis (p=0.001).In patients who were initially node positive, PR negativity was associated with a higher rate of axillary nodal PCR compared to those found to be PR positive(12.2% vs 25.5%; Chi Square test; p=0.04). ER+PR-HER- patients were more likely to have higher grade tumours but not LVI. Conclusion Over a quarter of ER+HER- patients who are PR negative will have a complete pathological response to NAC in the breast and axilla. Such patients should be considered for NAC at diagnosis.
Citation Format: Michael R Boland, Eanna J Ryan, Timothy Nugent, Darina Gilroy, John Kennedy, Dhaffir Alazawi, Terence J Boyle, Elizabeth M Connolly. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in oestrogen receptor positive breast cancer patients [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-16-11.
Abstract P3-02-11: Topographical ues overlaid with fructose-like molecules to assess breast cancer recruitment in nanofiber scaffolds
Authors: Que Carolynn , Hanumantharao Samerender Nagam , Vogl Brennan , Tanasova Marina , Rao Smitha 
Published: March 2020

Abstract
Tumorigenesis is a complex process involving numerous cellular signaling cascades and environmental factors. While 2D cultures for stiffness measurements and more recently 3D cultures to demonstrate differences in cell structures have been reported, very little is known about the impact of sugars in cell recruitment. In this study, we report the fabrication of 3D-scaffolds with different morphologies obtained by electrospinning with fluorescent fructose-like molecular probes to study cancer cell proliferation and migration. Using a FDA approved, biocompatible and biodegradable polymer Polycaprolactone (PCL), we electrospun nanofiber scaffolds having random, aligned, and honeycomb morphologies. Scaffolds with similar morphology without the fructose mimicking analogs were fabricated and used as controls. The degradation rate of the scaffolds was also characterized to ensure long-term availability of probes and mechanical stability of PCL. Cell viability, cell morphology, formation of colonies with changes in morphology were investigated. The changes in biophysical properties of tumor microenvironment with change in morphology of the scaffolds were investigated. In vitro tests for proliferation, alignment and migration of normal breast epithelial cells (184B5), adenocarcinoma (MCF-7), pre-malignant (MCF10AneoT) and triple-negative (MDAMB231 on the scaffolds on days 1, 2, and 3 were carried out. The morphology of the scaffolds was characterized using FE-SEM; cell proliferation was assessed using CellTiter-Blue® Viability Assay; migration and cell-scaffold interactions were investigated using phalloidin for F-Actin and fructose response was determined by immunostaining for facilitative fructose transporter GLUT-5. Our data indicates that while topographical features affected cell adhesion and proliferation, cell lines that responded to the fructose-like probes tended to be more invasive. Furthermore, the preference to a specific scaffold was greatly altered by the presence of the probes with MDAMB231 showing least preference after 72 hours and pre-malignant AneoT showing highest preference. However, there was no significant difference in the cell numbers between scaffolds with probes and those without for the pre-malignant cells while this difference was noticeable in the control cell lines. Further investigation into specific response to glucose and fructose uptake through their major transporters GLUT2 and GLUT5 are currently ongoing.
Citation Format: Carolynn Que, Samerender Nagam Hanumantharao, Brennan Vogl, Marina Tanasova, Smitha Rao. Topographical ues overlaid with fructose-like molecules to assess breast cancer recruitment in nanofiber scaffolds [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-02-11.
Abstract P3-03-04: Role of ABL kinase signaling in metastatic breast cancer colonization of the brain
Authors: McKernan Courtney Michelle , Pendergast Ann M 
Published: March 2020

Abstract
Breast cancer brain metastasis (BCBM) occurs in approximately 50% of late-stage Human Epidermal Growth Factor Receptor 2-positive (HER2+) breast cancer patients. BCBM may result in cognitive decline and cranial neuropathies and is associated with a median survival rate of nine months. Current therapies for BCBM, such as whole brain radiation therapy, can enhance cognitive impairment while targeted therapies and chemotherapy are ineffective. Despite the increased patient survival due to HER2 targeted therapies, patients often relapse due to brain metastases. Recently, our laboratory has discovered a role for Abelson (Abl) family of tyrosine kinases, ABL1 and ABL2, in breast cancer metastasis. Evaluation of 279 HER2+ breast cancer patients demonstrates a correlation between high expression of ABL1 and decreased distant metastasis free survival. Expression of ABL1 and ABL2 increase in brain metastatic breast cancer cells compared to parental cells, suggesting a role for the Abl kinases in breast cancer brain metastasis. I have found that treatment with the allosteric Abl kinase inhibitor GNF5 decreases colonization of the brain by two distinct human HER2+ breast cancer cell lines. Increasing evidence suggests that HER2 is upregulated in breast cancer cells colonizing the brain and may interact with the brain microenvironment to promote outgrowth. Both pharmacologic and genetic inhibition of the Abl kinases decreases HER2 protein expression in brain metastatic HER2+ breast cancer cells, potentially ablating the cell’s ability to proliferate in the brain. These data support a role for Abl kinases in promoting colonization of the brain by breast cancer cells. Due to its blood-brain barrier penetrance and efficacy in pre-clinical mouse models, Abl kinase-specific allosteric inhibitors may provide a novel therapeutic strategy for HER2+ breast cancer brain metastasis.
Citation Format: Courtney Michelle McKernan, Ann M Pendergast. Role of ABL kinase signaling in metastatic breast cancer colonization of the brain [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-03-04.
Abstract P3-03-10: Targeting Wnt/β-catenin pathway by antidepressant imipramine for triple negative breast cancer treatment
Authors: Rajamanickam Subapriya , Timilsina Santosh , Jatoi Ismoil , Kaklamani Virginia , Vadlamudi Ratna K , Rao Manjeet K 
Published: March 2020

Abstract
Aberrant activation of Wnt signaling has been implicated in various human cancers including breast cancer. Several intra-cellular signal transduction pathways are induced by Wnt, notably by Wnt/β-catenin dependent pathway. In breast cancer, triple negative breast cancer (TNBC) subtypes have increased Wnt/β-catenin signaling associated with high grade tumors, metastasis, poor prognosis and tumor regression. Importantly, significant upregulation of Wnt/β-catenin pathway and overexpression of Wnt transcriptional targets have emerged in breast cancer stem cells (BCSCs) than normal mammary epithelial stem cells. Blockade of Wnt/β-catenin signaling has been reported to suppress breast cancer growth, invasion, migration and induced apoptosis and “stemness”. WNT pathway inhibition preferentially reduces stem cell like activity in patient-derived metastatic breast cancer compared to normal cells. Collectively, these studies suggest that Wnt/β-catenin pathway could be the potential target in inhibiting TNBC growth, metastatic progression and “stemness”. We recently identified that imipramine, an FDA approved antidepressant used to treat chronic depression, inhibits TNBC growth and progression. Imipramine treatment significantly reduced cell viability, migration and invasion of breast cancer cells in general and TNBC cells in particular. Our preliminary findings demonstrated that systemic delivery of imipramine suppressed TNBC growth in orthotopic mouse xenograft model. Our studies further show that imipramine inhibits several Wnt/β-catenin catenin pathway proteins including WNT1, FZD1, β-catenin, cyclin D1 and c-myc, which are reported to support breast cancer “stemness” and metastasis. Importantly, our preliminary studies revealed that imipramine inhibits TNBC stem cells as evidenced by reduced CD44+ population. Our results suggest the therapeutic efficacy of imipramine as a single/or neo-adjuvant agent for treating TNBC patients.
Citation Format: Subapriya Rajamanickam, Santosh Timilsina, Ismoil Jatoi, Virginia Kaklamani, Ratna K Vadlamudi, Manjeet K Rao. Targeting Wnt/β-catenin pathway by antidepressant imipramine for triple negative breast cancer treatment [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-03-10.
Abstract P3-04-01: Telomere G-tail length correlates with the presence of breast cancer
Authors: Koi Yumiko , Tsutani Yasuhiro , Nishiyama Yukie , Sasada Shinsuke , Masumoto Norio , Kadoya Takayuki , Takahashi Ryou-u , Okada Morihito , Tahara Hidetoshi 
Published: March 2020

Abstract
Background The telomere G-tail, located at the terminal 3’-end, plays an important role in the maintenance of chromosome stability. Telomere G-tail length has been shown to be related to the presence of various cancers; however, the association between telomere G-tail length and breast cancer has remained unclear. Methods We measured the length of the leukocyte telomere G-tail using the hybridization protection assay, which has the advantages of being simple to perform, accurate and highly sensitive for G-tails as short as 20 nucleotides. The association between telomere G-tail length and presence of breast cancer was estimated by comparing breast cancer patients (n=70) and cancer-free individuals (n=83). We recruited cStage I-III breast cancer patients who underwent surgery between November 2016 and December 2017 at Hiroshima University Hospital. Cancer-free individuals included age-matched female individuals with no previous or current history of any cancer. Results The median telomere G-tail length was significantly shorter in breast cancer patients (11,886.70 ± 2,008.74 RLU/μg DNA) than in cancer-free individuals (13,336.00 ± 2,072.31 RLU/μg DNA; p &lt; 0.01). Shortening of the telomere G-tail length was observed in the phase of ductal carcinoma in situ, and this trend was observed with or without shortening of the total telomere length. Spearman’s rank correlation analysis showed that there was no significant association between telomere G-tail length and total telomere length in breast cancer patients (ρ = -0.09; p = 0.48). In contrast, a significant correlation was found between telomere G-tail length and total telomere length in cancer-free individuals (ρ = 0.29; p = 0.01). Conclusions Our study indicated that leukocyte telomere G-tail length may serve as a novel potential biomarker for detection of breast cancer.
Citation Format: Yumiko Koi, Yasuhiro Tsutani, Yukie Nishiyama, Shinsuke Sasada, Norio Masumoto, Takayuki Kadoya, Ryou-u Takahashi, Morihito Okada, Hidetoshi Tahara. Telomere G-tail length correlates with the presence of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-04-01.
Abstract P3-06-15: Identifying genomic alterations in stage IV breast cancer patients using MammaSeq: An international collaborative study
Authors: Soran Atilla , Sahin Mustafa , Ugras Serdar , Celik Esin , Shah Osama Shiraz , Lucas Peter C , Lee Adrian V 
Published: March 2020

Abstract
Background: Identification of genomic alterations present in cancer patients can aid in improving cancer diagnosis and prognosis. In this study, we aimed to identify clinically actionable variations present in stage IV breast cancer (BC) samples.
Methods: DNA was extracted from formalin fixed paraffin embedded samples of breast cancer (n=41). DNA was sequenced using MammaSeqTM, a breast cancer specific NGS panel targeting 79 genes and 1369 mutations. Ion Torrent Suite 4.0 was used to make variant calls on the raw data. Resulting single nucleotide variants (SNVs) were annotated using CRAVAT toolkit. CNVkit was employed to identify copy number variations (CNVs). The PMKB and OncoKB Precision Oncology Databases were used to associate clinical significance with the identified variants.
Results: A total of 41 BC patient samples were sequenced (read depth of 94 - 13340, median of 1529). In total, 96 different alterations (84 SNVs and 12 CNVs) were identified. Frequent SNVs were seen in PIK3CA, TP53, IKBKE, ATM and MAP3K1 genes. Moreover, amplifications were found in ERBB2, FGFR and AR, and deletions in BRCA2, RUNX1 and RB1. 3 CNVs (ERRB2, FGFR and AR amplifications) and 7 SNVs (IDH1.R132H, TP53.E204*, AKT1.E17K, PI3KCA.E545K, PI3KCA.H1047R, PI3KCA.R88Q and ERBB2.V777L) were reported as clinically significant by PMKB and OncoKB.
Conclusion: We identified 96 alterations in 50 genes in 41 stage IV BC tissue samples using MammaSeqTM. Ten of these alterations were reported as clinically significant. This study highlights the potential use of cancer specific NGS panels in clinic to get better insight into the cancer patient-specific genomic alterations.
Citation Format: Atilla Soran, Mustafa Sahin, Serdar Ugras, Esin Celik, Osama Shiraz Shah, Peter C Lucas, Adrian V Lee. Identifying genomic alterations in stage IV breast cancer patients using MammaSeq: An international collaborative study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-06-15.